Nasdaq · Healthcare

STANDARD BIOTOOLS INC. (LAB)

As-reported financials and recent SEC filings for STANDARD BIOTOOLS INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$85.3M

Net income

$-74.9M

Net margin

-87.8%

Diluted EPS

$-0.20

ROE

-17.7%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$85.3M	$91.0M	$106.3M	$97.9M	$130.6M
Gross profit	$42.5M	$44.9M	$50.5M	$37.1M	—
Operating income	$-110.2M	$-127.5M	$-76.6M	$-116.2M	$-67.5M
Net income	$-74.9M	$-138.9M	$-74.7M	$-190.1M	$-59.2M
Diluted EPS	$-0.20	$-0.52	$-0.23	$-0.61	$-0.20

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

8-K2026-06-18

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on LAB

Search STANDARD BIOTOOLS INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.